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A framework for human microbiome
research
The Human Microbiome Project Consortium*
A variety of microbial communities and their genes (the microbiome) exist throughout the human body, with
fundamental roles in human health and disease. The National Institutes of Health (NIH)-funded Human Microbiome
Project Consortium has established a population-scale framework to develop metagenomic protocols, resulting in a
broad range of quality-controlled resources and data including standardized methods for creating, processing and
interpreting distinct types of high-throughput metagenomic data available to the scientific community. Here we
present resources from a population of 242 healthy adults sampled at 15 or 18 body sites up to three times, which
have generated 5,177 microbial taxonomic profiles from 16S ribosomal RNA genes and over 3.5 terabases of
metagenomic sequence so far. In parallel, approximately 800 reference strains isolated from the human body have
been sequenced. Collectively, these data represent the largest resource describing the abundance and variety of the
human microbiome, while providing a framework for current and future studies.
Advances in sequencing technologies coupled with new bioinformatic
developments have allowed the scientific community to begin to invest-
igate the microbes that inhabit our oceans, soils, the human body and
elsewhere1.Microbesassociatedwith thehumanbody includeeukaryotes,
archaea, bacteria andviruses,withbacteria alone estimated tooutnumber
human cells within an individual by an order of magnitude. Our
knowledge of these communities and their gene content, referred to
collectively as the humanmicrobiome, has until now been limited by a
lack of population-scale data detailing their composition and function.
The US NIH-funded Human Microbiome Project Consortium
(HMP) brought together a broad collection of scientific experts to
explore these microbial communities and their relationships with their
human hosts. As such, the HMP2 has focused on producing reference
genomes (viral, bacterial and eukaryotic), which provide a critical
framework for subsequent metagenomic annotation and analysis, and
on generating a baseline of microbial community structure and func-
tion froman adult cohort defined by a carefully delineated set of clinical
inclusion and exclusion criteria that we term ‘healthy’ in this study
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id5
phd002854.2). Investigations of the microbiome from this cohort
incorporated several complementary analyses including: 16S ribosomal
RNA (rRNA) gene sequence (16S) and taxonomic profiles, whole-
genome shotgun (WGS) or metagenomic sequencing of whole com-
munityDNA, andalignment of the assembled sequences to the reference
microbial genomes from the human body3,4. Thus, the HMP comple-
ments other large-scale sequence-based human microbiome projects
such as the MetaHIT project5, which focused on examination of the
gutmicrobiomeusingWGSdata including samples from cohorts exhib-
iting a wide range of health statuses and physiological characteristics.
Additional projects supported by the HMP are investigating the
association of specific components and dynamics of the microbiome
with a variety of disease conditions, developing tools and technology
including isolating and sequencing uncultured organisms, and study-
ing the ethical, legal and social implications of human microbiome
research (http://commonfund.nih.gov/hmp/fundedresearch.aspx). A
comprehensive list of current publications from HMP projects is
available at http://commonfund.nih.gov/hmp/publications.aspx.
Here we detail the resources created so far by the HMP initiative
including: clinical specimens (samples), reference genomes, sequen-
cing and annotation protocols, methods and analyses. We describe
the thousands of samples obtained from 15 or 18 distinct body sites
from 242 donors over multiple time points that were processed at two
clinical centres (Baylor College of Medicine (BCM) and Washington
University School of Medicine). We also describe the laboratory and
computational protocols developed for reliably generating and inter-
preting the human microbiome data. HMP resources include both
protocols for, and the subsequent data generated from, 16S andmeta-
genomic sequencing of human microbiome samples. During this
study, these protocols were rigorously standardized and quality con-
trolled for simultaneous use across four sequencing centres (BCM
Human Genome Sequencing Center, The Broad Institute of
Massachusetts Institute of Technology (MIT) and Harvard, the
J. Craig Venter Institute and The Genome Institute at Washington
University School of Medicine). In particular, we focus on the pro-
duction of the first phase of metagenomic data sets (phase I) used for
subsequent in-depth analyses, and we summarize standards and
recommendations based on our experiences generating and analysing
these data. An additional set of publications (many included in the
references and in those of ref. 4) describe in further detail the micro-
bial ecology and microbiological implications of these data.
Collectively these resources and analyses represent an important
framework for human microbiome research.
HMP resource organization
Supplementary Fig. 1 summarizes organization of theHMP, including
the data processing and analytical steps, and the scientific entities
gathered to conduct the project. An overview of available HMP data
sets and additional resources are provided in Supplementary Tables
1–3. Donors were recruited and enrolled into the HMP through the
two clinical centres. Over 240 adults were carefully screened and phe-
notyped before sampling one to three times at 15 (male) or 18 (female)
body sites using a common sampling protocol (http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id5phd003190.2). All included
subjects were between the ages of 18 and 40 years and had passed a
*Lists of participants and their affiliations appear at the end of the paper.
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screening for systemic health based on oral, cutaneous and body mass
exclusion criteria (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
GetPdf.cgi?id5phd002854.2) (K.Aagaard et al., manuscript submitted).
A Data Analysis and Coordination Center (DACC) was created to
serve as the central repository for all HMP WGS, 16S and reference
genome sequence information generated by the four sequencing
centres. The DACC supports access to analysis software, biological
samples, clinical protocols, news, publication announcements and pro-
ject statistics, and performed centralized analysis of HMP reference
genome and WGS annotation in cooperation with the sequencing
centres. All unprocessed 16S, WGS and reference genome sequence
data are deposited at the National Center for Biotechnology Informa-
tion (NCBI) (http://www.ncbi.nlm.nih.gov/bioproject/43021). Unless
otherwise noted, all data sets and protocols described here are available
to the scientific community at theDACC(http://hmpdacc.org). Specific
data sets referred to in this work and available at the DACC are indi-
cated in parentheses with the preface ‘RES’.
Phase I 16S and WGS sequencing overview
A set of 5,298 samples were collected from 242 adults (K. Aagaard
et al., manuscript submitted; Table 1 and Supplementary Table 4),
from which 16S and WGS data were generated for a total of 5,177
taxonomically characterized communities (16S) and 681 WGS
samples describing the microbial communities from habitats within
the human airways, skin, oral cavity, gut and vagina. For a subset of
560 samples, both data types were generated (Table 1). These efforts
constitute our initial primary metagenomic data sets (phase I)
described in more detail later. Additional efforts are ongoing to
sequence and analyse the remaining samples from the complete
HMP collection (11,174 primary specimens in total from 300 indivi-
duals sampled up to three times over 22 months) (K. Aagaard et al.,
manuscript submitted).
16S standards development and sequencing
The goals of the HMP required that 16S sequences and profiles from
data produced at the four participating sequencing centres be com-
parable in a variety of downstream analyses; however, no suitable
methodology was available at the commencement of the project.
While establishing 16S protocols, we determined that many compo-
nents of data production and processing can contribute errors and
artefacts. We investigated methods that avoid these errors and their
subsequent effects on taxonomic classification and operational
taxonomic unit (OTU)-based community structure. The results are
discussed in detail in Supplementary Information and ref. 6. Thus,
multiple evaluations of 16S protocols were undertaken before adopt-
ing a single standardized protocol that ensured consistency in the
high-throughput production.
To maximize accuracy and consistency, protocols were evaluated
primarily using a synthetic mock community of 21 known organisms6
(Supplementary Table 5). Additional testing of the protocol was
carried out on a subset of HMP samples (Supplementary Table 1).
Collectively, these efforts resulted in adoption of a protocol to amplify
and sequence samples using the Roche-454 FLX Titanium platform6
(http://www.hmpdacc.org/doc/HMP_MDG_454_16S_Protocol.pdf).
TheHMP created both cellmixtures and genomicDNAextracts of the
mock community (Supplementary Tables 2 and 5). A large body of
metagenomic data (both 16S and WGS) (RES:HMMC) from these
and other calibration experiments are available to the community to
facilitate further benchmarking of new molecular and analytical
approaches (Supplementary Table 3).
The majority of the sample collection was targeted for 16S sequen-
cing using the 454 FLX Titanium based strategy6. The nucleotide
sequence of the 16S rRNA gene consists of regions of highly conserved
sequence, which alternate with nine regions or windows of variable
nucleotide sequence that constitute the most informative portions of
the gene sequence for use in taxonomic classification. A window
covering number three (V3) to five (V5) variable regions (V35) of
the 16S rRNA gene was chosen as the target for 4,879 samples.
Sequence of a V1 to V3 (V13) window was also included for a subset
of 2,971 samples to provide a complementary view of taxonomic
profiles6 (RES:HMR16S) (Table 1, Supplementary Figs 2, 3 and
Supplementary Information).
After adoption of the 16S protocol, including removal of multiple
sources of potential artefacts or bias generated by 16S sequencing
using pyrosequencing7,8, a variety of approaches for accurate diversity
estimation were developed and compared9. A 16S data processing
pipeline was established using the mothur software package10
(Supplementary Information), which includes two optional low and
high stringency approaches. The former provides an output favouring
longer read lengths tailored towards taxonomic classification, the latter
an output with more aggressive sequence error reduction tailored
towards OTU construction (RES:HMMCP). A third complementary
pipeline was also developed using the QIIME software package11
(Supplementary Information), which processes these data using an
Table 1 | HMP donor samples examined by 16S and WGS
Body region Body site Total
samples
Total 16S
samples
V13
samples
V13 read
depth (M)*
V35
samples
V35 read
depth (M)*
Samples
V13 and V35
Total WGS
samples
Total read
depth (G){
Filtered
reads
(%){
Human
reads
(%)1
Remaining
read depth
(G){
Samples
16S and
WGS
Gut Stool 352 337 193 1.4 328 2.4 184 136 1,720.7 15 1 1,450.6 124
Oral cavity Buccal mucosa 346 330 184 1.3 314 1.7 168 107 1,438.0 9 82 136.7 91
Hard palate 325 325 179 1.2 310 1.7 164 1 10.9 20 25 5.9 1
Keratinized gingiva 335 329 183 1.3 319 1.7 173 6 72.3 5 47 34.4 0
Palatine tonsils 337 332 189 1.2 315 1.9 172 6 74.8 2 80 13.5 1
Saliva 315 310 166 0.9 292 1.5 148 5 55.7 1 91 4.2 0
Subgingival plaque 334 328 186 1.2 314 1.8 172 7 92.1 5 79 15.3 1
Supragingival plaque 345 331 192 1.3 316 1.9 177 115 1,500.7 15 40 674.8 101
Throat 331 325 176 1.0 312 1.7 163 7 78.8 4 79 13.6 1
Tongue dorsum 348 332 193 1.3 320 2.0 181 122 1,620.1 15 19 1,084.3 106
Airway Anterior nares 316 302 169 1.0 283 1.2 150 84 1,129.9 3 96 14.3 70
Skin Left antecubital fossa 269 269 158 0.7 221 0.5 110 0 NA NA NA 0 NA
Left retroauricular crease 313 312 188 1.6 295 1.5 171 9 126.3 9 73 22.1 8
Right antecubital fossa 274 274 158 0.7 229 0.5 113 0 NA NA NA 0 NA
Right retroauricular crease 319 316 190 1.4 304 1.6 178 15 181.9 18 59 42.4 12
Vagina Mid-vagina 145 143 91 0.6 140 1.0 88 2 22.6 0 99 0.2 0
Posterior fornix 152 142 89 0.6 136 1.0 83 53 702.1 6 90 25.2 43
Vaginal introitus 142 140 87 0.6 131 0.9 78 3 36.5 1 98 0.6 1
Total 5,298 5,177 2,971 19 4,879 26.3 2,673 681 8,863.3 11 49 3,538.1 560
NA, not applicable.
*1 x106 reads post-processing with the mothur pipeline (Supplementary Information).
{1 x109 reads (Supplementary Information).
{Fraction of reads with low quality bases that were removed (Supplementary Information).
1Fraction of human reads that were removed (Supplementary Information).
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OTU-binning strategy to which taxonomic classification is added
(RES:HMQCP). All pipelines result in highly comparable views of
the human microbiome.
Metagenomic assembly and gene cataloguing
Approximately 749 samples representing targeted body sites were
chosen for WGS sequencing using the Illumina GAIIx platform with
101-base-pair paired-end reads. Fromahigh-quality set of 681 samples
an average depth of 13Gb (6 4.3)was achieved per sample, collectively
producing a total of 8.8 Tb (RES:HMIWGS) (Table 1). Theoretically,
these per sample data are sufficient to cover a 3Mb bacterial genome
present at only 0.8% abundance with a probability of 90% (M. C.
Wendl et al., manuscript submitted). In addition, 12 stool samples
were simultaneously sequenced using the 454 FLX Titanium platform
(RES:HM4WGS). Comparisons between the centres demonstrated
high consistency of target sequencing depth and success rates4. After
development of a protocol for removing reads resulting from human
DNA contamination (Supplementary Information), 49% of the reads
were targeted for removal as human (for information on authorized
access to these reads, see Supplementary Information). Samples
collected from soft tissue tended to have higher human contamination
(for example, mid-vagina (96%), anterior nares (82%) and throat
(75%)). Preparations from saliva were also high in human DNA
sequence (80%), whereas stool contained a relatively low abundance
of human reads (up to 1%) (Supplementary Fig. 4).
After application of a quality control protocol that includes human
sequence removal, quality filtering and trimming of reads (Sup-
plementary Information), the remaining 3.5 Tb from 681 samples
were subjected to a three-tiered complementary analysis strategy
(Supplementary Information) of reference genome mapping (which
was able to use ,57% of the data), assembly and gene prediction
(,50% of the data), and metabolic reconstruction (,36% of the
data). This combined strategy facilitated the extraction of maximal
organismal and functional information.
Metagenomic assemblies were generated for all available samples
using an optimized SOAPdenovo protocol with parameters designed
to produce substrates for downstream analyses such as gene and
function prediction, resulting in a total of 41 million contigs
(RES:HMASM) (Supplementary Information). Reads that remained
unassembled were pooled across individual body sites and re-
assembled using the same approach, resulting in an additional
4,200,672 contigs (RES:HMBSA). These body-site-specific assemblies
are aimed at reconstructing organisms that represent too small a
fraction in any individual sample to assemble but are found among
many individuals. For 12 stool samples both Illumina and 454 FLX
Titanium data (RES:HM4WGS) were generated, allowing a hybrid
assembly approach using Newbler (Supplementary Information)
(RES:HMHASM). Overall, the assembly statistics recovered varied
substantially depending on body site and community complexity
(Supplementary Fig. 5). However, our results indicate that, for the
assembly strategy we used, metagenomic assembly quality plateaus at
approximately 6Gb of microbial sequence coverage for a sample
possessing a microbial community structure similar to that of stool
samples (Supplementary Fig. 6).
A WGS-based perspective of community membership was obtained
by aligning the reads to a set of 1,742 finished bacterial, 131 archaeal,
3,683 viral and 326 microeukaryotic reference genomes12
(RES:HMREFG) (Supplementary Information) representing a broad
taxonomic range from each of these four domains. A total of 57.6% of
the high-quality microbial reads could be associated with a known
genome (ranging from33–77% for anterior nares and posterior fornix,
respectively) (RES:HMSCP). The overwhelming majority of mapped
sequences originated frombacteria (99.7%), while the remaining reads
mapped tomicroeukaryotes (0.3%) or archaea (,0.01%) (Supplemen-
tary Information).
Two complementary approaches were used to summarize overall
function and metabolism of the human microbiome, producing two
primary data sets of annotations (RES:HMMRC and RES:HMGI)
(Supplementary Information) and additional secondary analyses
(RES:HMGS, HMHGI, HMGC and HMGOI) (Supplementary
Information) available to the community for further interroga-
tion. The first primary data set of annotations was produced by
mapping individual shotgun reads to characterized protein families13
(RES:HMMRC). The second was produced from functionally
annotated gene predictions generated from the metagenomic
assemblies (RES:HMGI), which were subsequently grouped accord-
ing to high-level biological processes and to selected additional
processes specific to metabolism and regulation14 (RES:HMGS)
(Supplementary Tables 6, 7 and Supplementary Fig. 7).
HMP data generation and analysis lessons
A key manner in which the HMP resources will serve to guide future
studies of the microbiome is by enabling informed decisions regard-
ing sampling protocols and genomic DNA preparation (K. Aagaard et
al., manuscript submitted), sequencing depth (M. C. Wendl et al.,
manuscript submitted), statistical power (P. S. La Rosa et al., manu-
script submitted) andmetagenomic data type. As indicated in Table 1,
the consortium successfully amplified 16S sequences to our target
depth at all 18 body sites, with the fewest sequences recovered con-
sistently from the antecubital fossae. The amount of host human
DNA recovered and the finest level of OTU resolution varied for
16S sequences among body sites6 (Supplementary Figs 3 and 4).
FromourWGS investigations, a series of protocols (http://hmpdacc.
org/tools_protocols/tools_protocols.php) have been established to
process large volumes of short-read WGS data and to annotate and
examine these data through both a multi-tiered assembly approach
and as single reads15. An investigator’s choice of metagenomic
technologies can thus be guided not only by a 16S versus WGS
dichotomy, but also by the expected fraction of host sequence and
the appropriate 16S region targeting the dominant taxa at each body
site (Supplementary Figs 2–6 and 8).
Together, these data sets represent comprehensive and comple-
mentary views of the human microbiome, as shown by comparing
organismal (Fig. 1a) and gene (Fig. 1b) catalogues, and the ratio of
genes contributed per OTU (Fig. 1c). The discovery rate of new gene
clusters (as determined by annotation of assembled WGS data) is in
general detected more slowly relative to organismal discovery (as
determined by OTU data) owing to the fragmentary nature of these
community reads and assemblies despite high sequence depth
(Fig. 1a, b and Supplementary Fig. 9), and the number of genes con-
tributed per OTU varies by body site (Fig. 1c and Supplementary
Information). However, in general, these results highlight an import-
ant point for consideration of further microbiome investigations
using these data sets, as they suggest that the majority of the common
taxa and genes present in this reference population have been
detected.
We additionally compared the gut community gene catalogue
sampled by the HMP with that of MetaHIT in terms of total detected
gene counts. The HMP recovered more total non-redundant gene
counts (5,140,472) than reported by MetaHIT (3,299,822)5, probably
reflecting a combination of the increased sequence depth obtained by
theHMP (11.7GbHMP, 4.5GbMetaHIT on average) and differences
in data generation and processing5.
The two non-redundant sets of gene sequences were subsequently
combined and compared by matches to a database of orthologous
groups16 of functionally annotated genes. Approximately 57% of the
orthologous groups recovered by this method overlapped between the
data sets, while an additional 34% versus 10% were unique to the
HMP andMetaHIT, respectively (Supplementary Fig. 10, Supplemen-
tary Table 8 and Supplementary Information). After removal of genes
that received any orthologous group assignment, the remaining novel
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genes were subsequently clustered17. Approximately 79% of the HMP-
derived novel gene clusters were orthologous to one ormore clusters in
MetaHIT, while an additional 16%were unique to this study versus 5%
for MetaHIT-derived data5 (Supplementary Fig. 11, Supplementary
Table 8 and Supplementary Information). These results suggest that,
for this body habitat, relatively similar gene catalogues were recovered
despite differences in experimental design and protocols. However, a
greater proportion of both annotated and unique novel genes were
detected in the HMP data set, emphasizing the utility of sequencing
depth in recovering gene function and, in particular, deriving rare
function. These results further underscore the importance of large-
scale sequence-based studies of the microbiome to characterize better
its gene content and diversity.
Human microbiome reference genomes
The current goal for the reference genome component of the HMP is to
sequence at least 3,000 reference bacterial genomes, and additional viral
and microeukaryotic genomes, associated with the human body. Thus
far, more than 800 genomes have been sequenced and are available from
the NCBI and the DACC (http://hmpdacc.org/HMRGD). From an
alignment of WGS reads to reference genomes (RES:HMREFG),
approximately 26% from the total read set (46% of all reads that could
be aligned) were matched to a subset of 223 HMP reference genomes
(Supplementary Information and Supplementary Data).
We continue to solicit community feedback for strains that will
best benefit our attempts at understanding the breadth of human
microbiome diversity. For example, a prioritized list of the
‘most wanted’ HMP taxa is being maintained (http://hmpdacc.org/
most_wanted/) with the goal of targeting these difficult to obtain
organisms using both culture-based and single-cell approaches.
A catalogue of all HMP reference genomes along with custom
filtering, viewing, graphing and download options can be found at
the DACC Project Catalogue (http://www.hmpdacc-resources.org/
hmp_catalog/main.cgi). In addition, comparative analyses of reference
genomes are provided by the data warehouse and analytical systems,
IntegratedMicrobialGenomes/HMP(http://www.hmpdacc-resources.
org/cgi-bin/imgm_hmp/main.cgi). Cultures of all HMP reference strains
are required to be made publicly available through the Biodefense and
Emerging Infections Research Resources Repository (BEI). Information
on strain acquisition can be found at the DACC (http://hmpdacc.org/
reference_genomes/reference_genomes.php) and BEI (http://www.
beiresources.org/tabid/1901/stabid/1901/CollectionLinkID/4/Default.
aspx).
Conclusion
An overarching goal of this multi-year, multi-centre project is the
generation of a community resource to advance research efforts
related to the microbiome. The result is a collection of 11,174 primary
biological specimens representing the human microbiome, as well as
corresponding blood samples from the human donors, which are
being reserved for sequencing at a future date and from which cell
lines will be developed. A variety of new protocols were developed
to enable a project of this scope; these include methods for donor
recruitment, laboratory and sequence processing, and analysis of
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Figure 1 | Rates of gene and OTU discovery from HMP taxonomic and
metagenomic data. a–c, Accumulation curves for OTU counts from 16S data
(all body sites) (a), clustered gene index counts from metagenomic data (all
applicable body sites) (b) and the ratio of average unique genes contributed
versus unique OTUs encountered with increasing sample counts
(c) (Supplementary Information). L, left; R, right. Ratios given for each curve in
c represent the average number of unique genes contributed per uniqueOTUat
the final sample count. Curves for stool, buccal mucosa and anterior nares
suggest that the proportion of gene-to-taxa discovery has stabilized. In contrast,
the curve for supragingival plaque suggests that relatively fewer new genes are
being contributed per additional OTU. Error bars represent 95% confidence
intervals.
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16S andWGS sequence and profiles. These resources serve as models
to guide the design of similar projects. Studies with a primary focus on
disease can use this reference for comparative purposes, including
detecting shifts in microbial taxonomic and functional profiles, or
identification of new species not present in healthy cohorts that
appear under disease conditions. The catalogue described in this study
is, to our knowledge, the largest andmost comprehensive reference set
of human microbiome data associated with healthy adult individuals.
Collectively the data represent a treasure trove that can be mined to
identify new organisms, gene functions, andmetabolic and regulatory
networks, as well as correlations between microbial community struc-
ture and health and disease4. Among other future benefits, this resource
may promote the development of novel prophylactic strategies such as
the application of prebiotics and probiotics to foster human health.
METHODS SUMMARY
As part of a multi-institutional collaboration, the HMP human subjects study was
reviewed by the Institutional Review Boards (IRBs) at each sampling site: the BCM
(IRB protocols H-22895 (IRB no. 00001021) and H-22035 (IRB no. 00002649));
Washington University School of Medicine (IRB protocol HMP-07-001 (IRB no.
201105198)); andSt LouisUniversity (IRBno. 15778). The studywas also reviewed
by the J. Craig Venter Institute under IRB protocol 2008-084 (IRB no. 00003721),
and at the Broad Institute of MIT and Harvard the study was determined to be
exempt from IRB review. All study participants gave their written informed con-
sent before sampling and the study was conducted using the HumanMicrobiome
Project Core Sampling Protocol A. Each IRB has a federal-wide assurance and
follows the regulations established in 45 CFR Part 46. The study was conducted in
accordancewith the ethical principles expressed in theDeclaration ofHelsinki and
the requirements of applicable federal regulations.
All further details are in Supplementary Information.
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